States Food and Drug Administration (FDA) granted nirmatrelvir/ritonavir emergencyuseauthorization (EUA) to treat COVID‑19. It was approved in the United
concentration. In December 2021, the combination of nirmatrelvir and ritonavir was granted emergencyuseauthorization by the US Food and Drug Administration (FDA)
States Food and Drug Administration (FDA) granted nirmatrelvir/ritonavir emergencyuseauthorization (EUA) to treat COVID‑19. It was approved in the United
headaches, such as migraine headache. Nirmatrelvir/ritonavir (Paxlovid) — granted emergencyuseauthorization (EUA) by the US Food and Drug Administration
medication nirmatrelvir (formerly PF-07321332) became commercially available under emergencyuseauthorizations (EUA), as part of the nirmatrelvir/ritonavir